|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.335 EUR | +6.35% |
|
-1.33% | -14.10% |
| Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Celyad Oncology SA reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 0.044 million. Net loss was EUR 3.74 million compared to EUR 14.06 million a year ago.
Basic loss per share from continuing operations was EUR 0.17 compared to EUR 0.62 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.10% | 14.82M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
CELYAD ONCOLOGY SA 
